Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

CONCLUSIONS: BCI(H/I)-High vs -Low did not show a statistically significant difference in ELT benefit for the primary endpoint (RFI). However, in time-dependent DR analysis, BCI (H/I)-High patients experienced statistically significant benefit from ELT after 4y, whereas (H/I)-Low patients did not. Because BCI (H/I) has been validated as a predictive marker of EET benefit in other trials, additional follow-up may enable further characterization of BCI's predictive ability.PMID:38376912 | DOI:10.1158/1078-0432.CCR-23-1977

Source: Clinical Breast Cancer - February 20, 2024 Category: Cancer & Oncology Authors: Eleftherios P Mamounas Hanna Bandos Priya Rastogi Yi Zhang Kai Treuner Peter C Lucas Charles E Geyer Louis Fehrenbacher Stephen K Chia Adam M Brufsky Janice M Walshe Gamini S Soori Shaker Dakhil Soonmyung Paik Sandra M Swain Dennis C Sgroi Catherine A Sch Source Type: research